P. Sood

发表

Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol.

J. Cleveland, N. Uriel, M. Mehra, 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Association of Clinical Outcomes With Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent

J. Cleveland, Gene Kim, N. Uriel, 2020, JAMA cardiology.

Long‐term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure—two‐year results from the HeartMate 3 CE Mark Study

M. Morshuis, J. Garbade, V. Rao, 2018, European journal of heart failure.

A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report

M. Walsh, G. Ewald, J. Cleveland, 2019, The New England journal of medicine.

Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure

G. Ewald, J. Cleveland, V. Jeevanandam, 2017, Circulation.

Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure

G. Ewald, J. Cleveland, V. Jeevanandam, 2017 .

Clinical hemodynamic evaluation of patients implanted with a fully magnetically levitated left ventricular assist device (HeartMate 3).

D. Rodgers, N. Uriel, S. Adatya, 2017, The Journal of Heart and Lung Transplantation.

Multicentre clinical trial experience with the HeartMate 3 left ventricular assist device: 30-day outcomes.

M. Morshuis, J. Garbade, V. Rao, 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study.

M. Morshuis, J. Garbade, V. Rao, 2015, Journal of the American College of Cardiology.

Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study: Randomized Controlled Trial of a Magnetically Levitated Cardiac Pump in Advanced Heart Failure

J. Cleveland, N. Uriel, V. Thohan, 2018, Circulation.

Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF).

Akshay S. Desai, A. Desai, A. Ducharme, 2019, American heart journal.

Gender‐based evaluation of the XIENCE V™ everolimus‐eluting coronary stent system:

G. Stone, A. Lansky, V. Ng, 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Comparison of everolimus- versus paclitaxel-eluting stents implanted in patients with diabetes mellitus as evaluated by three-dimensional intravascular ultrasound analysis.

P. Fitzgerald, G. Stone, H. Otake, 2010, The American journal of cardiology.

Impact of routine angiographic follow-up after percutaneous coronary intervention with drug-eluting stents in the SPIRIT III randomized trial at three years.

G. Stone, A. Lansky, J. Hermiller, 2012, The American journal of cardiology.

Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial).

G. Stone, A. Lansky, V. Ng, 2011, The American journal of cardiology.

Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial

Akshay S. Desai, Andrew J. Sauer, A. Desai, 2021, The Lancet.

The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic

Akshay S. Desai, A. Desai, A. Ducharme, 2022, European heart journal.

Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials.

G. Stone, J. Hermiller, R. Applegate, 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Efficacy and Safety of the HeartMate Percutaneous Heart Pump During High-Risk Percutaneous Coronary Intervention (from the SHIELD I Trial).

J. Granada, D. Dudek, M. Zembala, 2018, The American journal of cardiology.

Early Reduction in Ambulatory Pulmonary Artery Pressures After Initiation of Sacubitril/Valsartan.

Akshay S. Desai, A. Desai, L. Stevenson, 2021, Circulation. Heart failure.

Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo‐controlled, non‐inferiority ARIES HM3 trial

N. Uriel, F. Pagani, M. Mehra, 2021, European journal of heart failure.

Impact of left ventricular assist device implantation on mitral regurgitation: An analysis from the MOMENTUM 3 trial.

J. Cleveland, N. Uriel, M. Mehra, 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.

G. Stone, A. Lansky, J. Hermiller, 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De

G. Stone, A. Lansky, D. Kereiakes, 2010, JACC. Cardiovascular interventions.

Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus eluting coronary stent system.

C. Bol, J. Saucedo, P. Sood, 2010, Journal of interventional cardiology.

Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.

G. Stone, A. Lansky, J. Hermiller, 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Evaluation of XIENCE V everolimus-eluting and Taxus Express2 paclitaxel-eluting coronary stents in patients with jailed side branches from the SPIRIT IV trial at 2 years.

G. Stone, A. Lansky, D. Kereiakes, 2013, The American journal of cardiology.

Initial experience with the HeartMate percutaneous heart pump in circulatory failure.

U. Jorde, P. Sood, P. Ivák, 2017, The Journal of Heart and Lung Transplantation.

Evaluation of low-intensity anti-coagulation with a fully magnetically levitated centrifugal-flow circulatory pump-the MAGENTUM 1 study.

M. Mehra, J. Connors, J. Rimsans, 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Two‐Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure

James W Long, Arun Krishnamoorthy, Valluvan Jeevanandam, 2018, The New England journal of medicine.

Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure.

M. Mehra, J. Connors, Kartik Sundareswaran, 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

First 5-year multicentric clinical trial experience with the HeartMate 3 left ventricular assist system.

M. Morshuis, E. Potapov, J. Garbade, 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

DES Overview: A Historical and Current Review of Pivotal Clinical Trial Programs

C. Simonton, P. Sood, K. Sudhir, 2012 .

Clinical Trials in Interventional Cardiology: Focus on XIENCE V Drug‐Eluting Stent

W. Cheong, P. Sood, L. Schwartz, 2010 .

Periprocedural Myocardial Infarction in a Randomized Trial of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents: Frequency and Impact on Mortality According to Historic Versus Universal Definitions

G. Stone, D. Kereiakes, D. Cutlip, 2012, Circulation. Cardiovascular interventions.

A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis.

P. Serruys, G. Stone, A. Lansky, 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study.

J. Cleveland, N. Uriel, S. Najjar, 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.

P. Fitzgerald, G. Stone, K. Mahaffey, 2008, JAMA.

Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).

G. Stone, D. Kereiakes, D. Cutlip, 2010, Journal of the American College of Cardiology.

Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trial.

J. Cleveland, N. Uriel, V. Thohan, 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everol

P. Serruys, G. Stone, A. Lansky, 2011, JACC. Cardiovascular interventions.

Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV clinical trials.

G. Stone, J. E. Maddux, J. Hermiller, 2011, Journal of interventional cardiology.

Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial.

G. Stone, J. Hermiller, P. Sood, 2009, American heart journal.

Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial).

G. Stone, A. Lansky, D. Cutlip, 2011, The American journal of cardiology.

Low stent thrombosis risk with the XIENCE V® Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials.

A. Lansky, J. Hermiller, P. Sood, 2011, Journal of interventional cardiology.

Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent

P. Sood, K. Sudhir, Julie Doostzadeh, 2010, Coronary artery disease.

Predictors of early and late outcomes after everolimus and paclitaxel-eluting coronary stents.

G. Stone, J. Hermiller, R. Applegate, 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial.

Gregg W Stone, G. Stone, D. Kereiakes, 2011, Journal of the American College of Cardiology.

Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials.

P. Serruys, G. Stone, M. Fahy, 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

(151) - HeartMate 3 Fully Magnetically Levitated Left Ventricular Assist Device for the Treatment of Advanced Heart Failure - CE Mark Study 2-Year Results

M. Morshuis, J. Garbade, V. Rao, 2017 .

Echocardiographic Changes in Patients Implanted With a Fully Magnetically Levitated Left Ventricular Assist Device (Heartmate 3).

T. Imamura, N. Uriel, F. Maffessanti, 2019, Journal of cardiac failure.

A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report

M. Walsh, G. Ewald, J. Cleveland, 2019, The New England journal of medicine.

Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure.

M. Mehra, J. Connors, Kartik Sundareswaran, 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Effect of HeartMate PHP on Resting Hemodynamics in Low Cardiac Output Patients Undergoing Elective High-Risk PCI

J. Granada, D. Dudek, A. Witkowski, 2016 .

Clinical hemodynamic evaluation of patients implanted with a fully magnetically levitated left ventricular assist device (HeartMate 3).

D. Rodgers, N. Uriel, S. Adatya, 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.